Rochelle, Virginia (February 21, 2018) – NDA Partners Chairman Carl Peck, MD, announced today that Richard Kim, MD, an expert in neurology and drug development and former Chief Medical Officer and Senior Vice President of Clinical Development and Medical Affairs at XenoPort, has joined the firm as an Expert Consultant. Dr. Kim is an expert in a wide range of indications, including multiple sclerosis, psoriasis, restless legs syndrome, amyotrophic lateral sclerosis, alcohol use disorder, and post-herpetic neuralgia.
Dr. Kim is a well-diversified pharmaceutical executive with 15-years of experience in both clinical development and medical affairs at small to mid-sized biopharmaceutical companies. He has worked on development of significant new products that have been approved in the U.S. and globally, such as Tysabri, Horizant, Cladribine, Butrans, and Rebif.
In addition to his position at XenoPort, Dr. Kim served as Vice President, Clinical Development and Head of MS Therapeutic Area at Elan Pharmaceuticals; Global Medical Director, Medical Affairs at Biogen Idec; Medical Director, Clinical Development at EMD Serono, and Associate Medical Director, Clinical Pharmacology at Purdue Pharma.
“Dr. Kim’s expertise will significantly enhance our ability to provide best-in-class advice to our clients that are developing new drugs, particularly for the treatment of neurological and autoimmune disorders. We are very pleased that he has joined NDA Partners’ team of Expert Consultants,” said Dr. Peck.
Dr. Kim earned his medical degree from Tulane University School of Medicine and a Bachelor of Science degree in biology from the University of California, Los Angeles. He completed his neurology residency at Stanford University. He is board-certified by the American Board of Psychiatry and Neurology and a member of the American Academy of Neurology.
About NDA Partners
NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of more than 100 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.
Earle Martin, Chief Executive Officer